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Abstract Elevated level of DNA damage was observed in
patients with depression. Furthermore, single nucleotide poly-
morphisms (SNPs) of base excision repair (BER) genes may
modulate the risk of this disease. Therefore, the aim of this
study was to delineate the association between DNA damage,
DNA repair, the presence of polymorphic variants of BER
genes, and occurrence of depression. The study was conduct-
ed on peripheral blood mononuclear cells of 43 patients diag-
nosed with depression and 59 controls without mental disor-
ders. Comet assay was used to assess endogenous (oxidative)
DNA damage and efficiency of DNA damage repair (DRE).
TaqMan probes were employed to genotype 12 SNPs of BER
genes. Endogenous DNA damage was higher in the patients
than in the controls, but none of the SNPs affected its levels.
DRE was significantly higher in the controls and was modu-
lated by BER SNPs, particularly by c.977C>G–hOGG1,
c.972G>C–MUTYH, c.2285T>C–PARP1, c.580C>T–
XRCC1, c.1196A>G–XRCC1, c.444T>G–APEX1, c.-
468T>G–APEX1, or c.*50C>T–LIG3. Our study suggests
that both oxidative stress and disorders in DNA damage repair
mechanisms contribute to elevated levels of DNA lesions ob-
served in depression. Lower DRE can be partly attributed to
the presence of specific SNP variants.
Keywords Recurrent depression disorder . DNA damage .
DNA repair . Oxidative stress . Base excision repair . Single
nucleotide polymorphism
Introduction
Even though depression disorder (including the recurrent
type—rDD) is common, its pathogenesis still remains elusive.
Activation of immune-inflammatory pathways plays a key
role in the onset of depression [1, 2]. It is indicated by high
levels of pro-inflammatory cytokines and elevated expression
of the NOD-like receptor family, pyrin domain containing 3
(NLRP3), a component of the inflammasome which releases
pro-inflammatory cytokines [3–6]. NLRP3 is involved in
DNA damage response (DDR) since its knockout increases
the effectiveness of double-strand break repair and base exci-
sion repair (BER) [7]. The activated immune-inflammatory
pathways present in depression often coexist with increased
oxidative stress, as indicated by elevated levels of lipid perox-
idation and production of reactive oxygen species (ROS) in
patients affected by the disease [6, 8]. Oxidative damage to
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DNA is one of the consequences of oxidative stress in depres-
sion and is indicated by increased 8-oxoguanine (8-oxoG) in
the urine, serum, and peripheral blood mononuclear cells
(PBMCs) of depressed patients [9–14]. However, the urinary
levels of 8-oxoG in patients with milder, non-clinical depres-
sion did not differ from the healthy controls [15]. Our previous
study utilizing comet assay technique on the PBMCs of pa-
tients diagnosed with clinical depression confirmed the pres-
ence of not only oxidatively modified purines and pyrimidines
but also other types of DNA damage, like DNA strand breaks
[16]. Furthermore, we also noted that increased DNA damage
in patients with depression might be caused not only by the
disease itself but also by the impairments of oxidative DNA
damage repair, since we observed that the patients’ cells
repaired DNA damage induced by hydrogen peroxide
(H2O2) more slowly than the controls’ cells [17]. Since it
was shown that single nucleotide polymorphism (SNP) vari-
ants of genes involved in DDR, particularly BER, may nega-
tively affect the process, we genotyped the SNPs of genes
involved in this repair pathway [16–18].We showed that some
of these polymorphic variants increased the risk of rDD while
others decreased this risk [16].
Therefore, in the present study, we delineate whether SNPs
of genes involved in BERmay affect DNA damage repair. We
have genotyped 12 SNPs located in either coding or regulato-
ry regions of BER genes and estimated the level of endoge-
nous DNA damage as well as the efficiency of DNA damage




Participants of this study consisted of 43 patients with rDD
(mean age, 49.3 ± 10.2 years) hospitalized at the Department
of Adult Psychiatry of the Medical University of Lodz
(Poland) and 59 healthy controls (mean age, 51.2 ± 13.3 years)
randomly selected without replacement sampling. Inclusion
criteria and diagnosis were based on those outlined in ICD-
10 (F32.0-7.32.2 and F33.0-F33.8) [20]. Standardized
Composite International Diagnostic Interview (CIDI) was
used to obtain a medical history for all cases [21]. Cases with
axis I and axis II disorders other than depression, inflamma-
tory, or autoimmune disorders were excluded as well as those
with severe and chronic somatic diseases or worsening of
symptoms and injuries of the central nervous system. Blood
samples were taken from the rDD patients before they were
subjected to an antidepressant therapy with drugs from the
selective serotonin reuptake inhibitor group. Detailed infor-
mation about patients are presented in Table 1. Respondents
without cases of mental illness in their medical history were
randomly selected to form the control group. According to the
protocol approved by the Bioethics Committee of the Medical
University of Lodz (no. RNN/70/14/KE), an informed written
consent was obtained from each participant.
Blood Collection
Tenmilliliters of venous blood was taken from the participants
after period of fasting. Blood samples were stored at 4 °C and
the isolation of PBMCs was done within 4 h after the collec-
tion. Additionally, blood from depressed patients was obtain-
ed before the pharmacological treatment started. An aliquot of
500 μl of blood was frozen and stored at −20 °C until the
isolation of DNA.
DNA Isolation
DNA was isolated from venous blood using Blood Mini Kit
(A&A Biotechnology, Gdynia, Poland). Its purity was con-
trolled by acquiring the absorbance ratio at 260 and 280 nm.
Selection of Single Nucleotide Polymorphism
and Genotyping
Selection of the SNPs was performed using the public domain
of the National Center for Biotechnology Information, the
Single Nucleotide Polymorphisms database at http://www.
ncbi.nlm.nih.gov/snp (Bethesda, MD, USA). The following
criteria were used to choose the SNPs: a minor allele
frequency higher than 0.05 in a European population
(submitter population ID: HapMap-CEU); localization in
coding region causing non-synonymous substitution or in reg-
ulatory regions; and presence in the literature concerning dis-
eases other than depression in pathogenesis in which oxidative
stress and increased DNA damage play a major role.
TaqMan® SNP Genotyping Assay with TaqMan Fast
Universal PCR Master mix (Life Technologies, Carlsbad,
CA, USA) were used to genotype the studied SNPs.
Reactions were performed in conditions recommended by
the manufacturer in a Bio-Rad CFX96 thermal cycler with
Real-Time PCR Detection System (Bio-Rad Laboratories
Inc., Hercules, CA, USA). Results were analyzed in CFX
Manager Software (Bio-Rad Laboratories Inc.).
Table 1 Course of depression in the rDD group
Variable rDD (N = 43), M (SD)
HDRS 23.74 (5.74)
No. of depression episodes 6.92 (5.81)
Disease duration 4.63 (3.21)
rDD recurrent depressive disorder, HDRS Hamilton Depression Rating
Scale at the onset of therapy, M mean, SD standard deviation
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Peripheral Blood Mononuclear Cell Isolation
and Treatment
Isolation of PBMCs was performed by isopycnic centrifuga-
tion (30°min, 400×g, 4 °C) of blood in Histopaque-1077
(Sigma-Aldrich, St. Louis, MO, USA). The obtained cells
were then immediately counted in Bürcker chamber and used
in the experiments. The level of DNA damage detected in
untreated PBMCs was considered as endogenous DNA dam-
age. To assess the efficacy of DDR, firstly, PBMCs were ex-
posed to 20μMH2O2 for 10min on ice (POCH S.A., Gliwice,
Poland). Then, PBMCs were washed and suspended in fresh
RPMI-1640 medium for 120 min at 37 °C and the level of
DNA damage was measured at the beginning and after
120 min of repair incubation.
Comet Assay
DNA damage in PBMCs was estimated by the alkaline ver-
sion (pH > 13) of the comet assay according to the procedure
described by Singh et al. with later modifications [22–24].
Since this technique recognizes only DNA strand breaks and
alkali labile sites, two glycosylases—Nth or human 8-
oxoguanine DNA glycosylase (endonuclease III and
hOOG1, respectively; New England Biolabs, Ipswich, MA,
USA)—were used to detect oxidative DNA damage accord-
ing to the procedure described earlier [25]. hOOG1 recognizes
and removes 8-oxoadenine when paired with cytosine and 7,
8-dihydro-8-oxoguanine (8-oxoguanine) when paired with
cytosine, methyl-fapy-guanine, and foramidopyrimidine
(fapy)-guanine [26, 27]. Nth recognizes and removes urea,
thymine glycol, 5,6-dihydroxythymine, uracil glycol, 5-hy-
droxy-5-methylhydanton, 6-hydroxy-5,6-dihdrothimine, and
methyltartronylurea [28, 29].
Each sample containing 5 × 105 PBMCs was centrifuged
(250×g, 15 min, 4 °C), suspended in 1.13 % agarose type XI
(Sigma-Aldrich), cast on a microscope slide pre-coated with
0.5% low electroendosmosis agarose type I (Sigma-Aldrich),
covered with a cover glass, and gelled on a cold plate for
10 min. Then, the cover glass was removed and the slide
was incubated overnight in a lysis solution (2.5 mM NaCl,
100 mM Tris, 10 mM EDTA, 1 % Triton X-100, pH 10) at
4 °C. After lysis, slides were left for 20 min in buffer contain-
ing 300mMNaOH and 1mMEDTA, allowing the unwinding
of DNA. Lastly, the 20-min electrophoresis was conducted at
an electric field strength of 0.73 V/cm (300 mA) in a buffer of
pH > 13 (300 mM NaOH and 1 mM EDTA).
The incubation with glycosylases was performed after ly-
sis. These samples were washed with enzyme buffer (0.1 M
KCl, 0.5 mM EDTA, 40 mM HEPES, 0.2 mg/ml bovine se-
rum albumin, pH 8) and treated for 1 h with 1 U of
OGG1/Nth, or with the buffer alone as a control at 37 °C.
After incubation completion, unwinding and electrophoresis
were conducted as described previously.
When electrophoresis ended, slides were washed
twice with deionized water and left to dry out. For
analysis, samples were stained for at least 60 min with
1 μg/ml DAPI, and then the comet pictures were cap-
tured in an Eclipse fluorescence microscope (Nikon,
Tokyo, Japan) with a COHU 4910 video camera
(Cohu, San Diego, CA, USA) and measured with
Lucia-Comet image analysis system (Laboratory
Imaging, Praha, Czech Republic). For each sample, 50
comets were analyzed; DNA damage levels are present-
ed as a mean of the percentage of DNA in the tail of
the comets. Results for samples digested with the DNA
repair enzymes were normalized by subtracting the level
of DNA damage evoked by enzyme buffer only.
Statistical Analysis
Statistical analysis of the gathered data was performed in
Statistica 12 (Statsoft, Tulsa, OK, USA) and SigmaPlot
11.0 (Systat Software Inc., San Jose, CA, USA). The as-
sociation between case/control and each polymorphism
was calculated using an unconditional multiple logistic
regression model, and the results are shown as odds ratios
(ORs) with 95 % confidence interval (95% CI). Data pre-
senting the results from the comet assay analysis are
shown as the mean ± SEM from two separate experiments.
Normality of distribution of the data was examined by the
Kolmogorov–Smirnov test and equality of variances by F
test. Significance of the difference between the studied
values was determined by Mann–Whitney test if both or
one of the tests failed; otherwise, it was determined by
Student’s t test. The efficiency of DRE was calculated





where TD120 is the percentage of DNA in the comet tail
after 120 min repair incubation and TD0 is the percentage
of DNA in the comet tail after exposure to hydrogen
peroxide.
Results
Distribution of Genotypes of the Studied Polymorphisms
The distribution of SNP genotypes is shown in Table 2. The dis-
tribution of genotypes in all cases was in agreement with the
Hardy–Weinberg equilibrium. Among the studied SNPs, only
G/T heterozygote of c.-468T>G–APEX1 was significantly
Mol Neurobiol
associatedwith increasedriskofrDD.InSupplementaryTables1,
2, 3, 4, 5, 6, 7, and 8, we present additional analysis, where we
divided the studied group into individuals with either higher or
lower than median DRE, basal DNA damage recognized by the
alkaline version of the comet assay, and oxidative DNA damage
recognized byNth or hOGG1.
Basal Endogenous DNA Damage
Table 3 presents the total basal DNA damage in depressed
patients and controls, classified according to polymorphic var-
iants. If there were less than three cases with either minor
allele or heterozygote, these two groups were merged. We
Table 2 Distribution of
genotypes and alleles of the
studied single nucleotide
polymorphism and the risk of
recurrent depression disorder
Genotype/allele N (frequency) Crude OR (95% CI) p
Controls (59) Depression (43)
NEIL1 c.*589G4C (rs4462560)
C/C 39 (0.661) 34 (0.791) 1.937 (0.779–4.819) 0.155
C/G 19 (0.322) 7 (0.168) 0.409 (0.154–1.087) 0.073
G/G 1 (0.017) 2 (0.047) 2.829 (0.248–32.251) 0.402
C/G and G/G 20 (0.339) 9 (0.209) 0.516 (0.208–1.284) 0.155
hOGG1 c.977C>G (rs1052133)
C/C 39 (0.661) 31 (0.721) 1.325 (0.562–3.122) 0.520
C/G 16 (0.271) 12 (0.279) 1.040 (0.432–2.507) 0.930
G/G 4 (0.068) 0 (–) – –
C/G and G/G 20 (0.339) 12 (0.279) 0.755 (0.30–1.779) 0.520
MUTYH c.972G>C (rs3219489)
C/C 40 (0.678) 26 (0.605) 0.726 (0.320–1.649) 0.445
C/G 17 (0.288) 13 (0.302) 1.071 (0.453–2.532) 0.877)
G/G 2 (0.034) 4 (0.093) 2.923 (0.510–16.747) 0.228
C/G and G/G 19 (0.322) 17 (0.395) 1.77 (0.606–3.124) 0.445
PARP1 c.2285T>C (rs1136410)
A/A 36 (0.610) 32 (0.744) 1.859 (0.785–4.401) 0.159
A/G 21 (0.356) 10 (0.233) 0.548 (0.226–1.330) 0.184
G/G 2 (0.034) 1 (0.023) 0.679 (0.060–7.733) 0.755
A/G and G/G 23 (0.390) 11 (0.256) 0.538 (0.227–1.274) 0.159
XRCC1 c.1196A>G (rs25487)
C/C 22 (0.373) 14 (0.326) 0.812 (0.355–1.858) 0.622
C/T 31 (0.525) 24 (0.558) 1.141 (0.518–2.513) 0.743
T/T 6 (0.102) 5 (0.116) 1.162 (0.330–4.089) 0.815
XRCC1 c.580C>T (rs1799782)
G/G 50 (0.847) 40 (0.930) 2.400 (0.609–9.456) 0.211
G/A 9 (0.153) 3 (0.070) 0.417 (0.106–1.642) 0.211
A/A 0 (–) 0 (–) –
FEN1 c.-441G>A (rs174538)
G/G 29 (0.492) 26 (0.605) 1.582 (0.713–3.508) 0.259
G/A 30 (0.508) 17 (0.395) 0.632 (0.285–1.402) 0.259
A/A 0 (–) 0 (–) – –
APEX1 c.-468T>G (rs1760944)
G/G 9 (0.153) 5 (0.116) 0.731 (0.226–2.359) 0.600
G/T 26 (0.441) 28 (0.651) 2.369 (1.053–5.330) 0.037
T/T 24 (0.407) 10 (0.233) 0.442 (0.184–1.063) 0.068
APEX1 c.444T>G (rs1130409)
G/G 15 (0.254) 12 (0.279) 1.135 (0.468–2.758) 0.779
G/T 31 (0.525) 17 (0.395) 0.591 (0.266–1.310) 0.195
T/T 13 (0.220) 14 (0.326) 1.708 (0.704–4.145) 0.236
LIG1 c.-7C>T (rs20579)
G/G 48 (0.814) 33 (0.767) 0.756 (0.288–1.984) 0.570
G/A 9 (0.153) 10 (0.233) 1.684 (0.618–4.586) 0.308
A/A 2 (0.034) 0 (–) – –
G/A and A/A 11 (0.186)) 10 (0.233) 1.322 (0.504–3.468) 0.570
LIG3 c.*50C>T (rs1052536)
C/C 14 (0.237) 8 (0.186) 0.735 (0.277–1.947) 0.535
C/T 27 (0.458) 20 (0.465) 1.031 (0.469–2.267) 0.940
T/T 18 (0.305) 15 (0.349) 1.220 (0.528–2.818) 0.641
LIG3 c.*83A>C (rs4796030)
A/A 9 (0.153) 5 (0.116) 0.731 (0.226–2.359) 0.600
A/C 26 (0.441) 18 (0.419) 0.914 (0.413–2.023) 0.824
C/C 24 (0.407) 20 (0.465) 1.268 (0.574–2.803) 0.557
p < 0.05 along with corresponding ORs are in bold
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found that the patients with rDD had significantly higher en-
dogenous DNA damage than the controls (p < 0.001).
Moreover, we demonstrated that the level of DNA damage
in each genotype of the studied polymorphisms was signifi-
cantly higher in the depressed patients when compared to the
controls (p < 0.05), but there was no difference between the
genotypes within the groups (p > 0.05). Also, when we divid-
ed the population into those with higher and lower than me-
dian basal DNA damage, in each case, this damage was higher
in the patients compared to the controls (Supplementary
Tables 9 and 10). In a similar fashion to Table 3, Tables 4
and 5 present the mean oxidative DNA damage recognized
by hOGG1 and Nth, respectively. In all cases, except for the
heterozygote of c.580C>T–XRCC1, we found that depressed
patients had higher oxidative DNA damage than those in the
control group (p < 0.05) and that the differences between ge-
notypes within these groups were not statistically significant
(p > 0.05).
Efficiency of DNA Damage Repair
In the overall studied population, DREwas significantly lower
in the cases when compared to the controls (p < 0.001; Table 6
and Fig. 1). However, we did not find any statistically signif-
icant difference between the patients and controls in individ-
uals with the following genotypes: combination of C/G and
G/G of c.977C>G–hOGG1, combination of C/G and G/G of
c.972G>C–MUTYH, combination of A/G and G/G of
c.2285T>C–PARP1, T/T of c.1196A>G–XRCC1, G/A of
c.580C>T–XRCC1, T/T of c.-468T>G–APEX1, T/T of
c.444T>G–APEX1, and C/C and T/T of c.*50C>T–LIG3
(Table 6). Moreover, within the groups of cases and controls,
no statistically significant difference was found between the
different genotype carriers (Table 6). Moreover, in individuals
with rDD and with DRE higher than the median, we found
differences between carriers of the genotypes of c.977C>G–
hOGG1 and c.972G>C–MUTYH (Table 7), while in the pa-
tients with lower than the median DRE, such differences were
present between carriers of the genotypes of c.2285T>C–
PARP1 and c.-7C>T–LIG1 (Table 8).
Discussion
A growing body of evidence suggests that elevated ROS and
peroxidation of lipids both indicating oxidative stress, togeth-
er with activated immune-inflammatory pathways, are present
in depressed patients and may play an important role in the
pathogenesis of this mental disorder [6, 8]. Moreover, in the
serum, urine, and PBMCs of patients suffering from clinical
symptoms of depression, elevated levels of 8-oxoG were
found, showing that oxidative stress may compromise genetic
material [9–14]. Our recent studies also demonstrated, via the
comet assay, the significantly higher level of oxidatively mod-
ified purines and pyrimidines in PBMCs from depressed
Table 3 Basal endogenous DNA damage
Genotype Tail DNA (%), mean ± SEM pa
Control Depression
Total
– 1.86 ± 0.16 6.94 ± 0.55 <0.001
NEIL1 c.*589G4C (rs4462560)
C/C 1.74 ± 0.18 6.71 ± 0.64 <0.001
C/G and G/G 2.08 ± 0.29 7.78 ± 1.04 <0.001
pb 0.337 0.310
hOGG1 c.977C>G (rs1052133)
C/C 1.83 ± 0.20 6.73 ± 0.67 <0.001
C/G and G/G 1.90 ± 0.24 7.47 ± 0.96 <0.001
pb 0.608 0.417
MUTYH c.972G>C (rs3219489)
C/C 1.75 ± 0.18 6.54 ± 0.54 <0.001
C/G and G/G 2.08 ± 0.29 7.54 ± 1.12 <0.001
pb 0.368 0.619
PARP1 c.2285T>C (rs1136410)
A/A 1.96 ± 0.21 7.15 ± 0.69 <0.001
A/G and G/G 1.69 ± 0.23 6.23 ± 0.83 <0.001
pb 0.401 0.679
XRCC1 c.1196A>G (rs25487)
C/C 1.50 ± 0.24 7.05 ± 0.84 <0.001
C/T 1.97 ± 0.20 6.65 ± 0.84 <0.001
T/T 2.55 ± 0.66 8.03 ± 1.03 0.001
pb 0.084 0.304
XRCC1 c.580C>T (rs1799782)
G/G 1.82 ± 0.17 6.87 ± 0.58 <0.001
G/A 2.04 ± 0.45 7.78 ± 1.46 0.016
pb 0.635 0.404
FEN1 c.-441G>A (rs174538)
G/G 1.80 ± 0.21 6.45 ± 0.41 <0.001
G/A 1.91 ± 0.24 7.67 ± 1.24 <0.001
pb 0.940 0.960
APEX1 c.-468T>G (rs1760944)
G/G 1.95 ± 0.25 7.36 ± 1.12 <0.001
G/T 1.71 ± 0.25 6.89 ± 0.72 <0.001
T/T 2.03 ± 0.27 6.34 ± 1.34 0.008
pb 0.438 0.875
APEX1 c.444T>G (rs1130409)
G/G 1.63 ± 0.25 8.59 ± 1.44 <0.001
G/T 1.81 ± 0.21 6.27 ± 0.77 <0.001
T/T 2.27 ± 0.41 6.33 ± 0.58 <0.001
pb 0.545 0.242
LIG1 c.-7C>T (rs20579)
G/G 1.89 ± 0.17 7.05 ± 0.68 <0.001
G/A and A/A 1.71 ± 0.38 6.55 ± 0.81 <0.001
pb 0.559 1.000
LIG3 c.*50C>T (rs1052536)
C/C 2.17 ± 0.40 5.22 ± 0.82 0.001
C/T 1.88 ± 0.20 7.68 ± 1.02 <0.001
T/T 1.58 ± 0.28 6.86 ± 0.60 <0.001
pb 0.448 0.365
LIG3 c.*83A>C (rs4796030)
A/A 1.77 ± 0.39 5.50 ± 0.77 <0.001
A/C 1.98 ± 0.21 7.27 ± 1.08 <0.001
C/C 1.75 ± 0.27 7.00 ± 0.65 <0.001
pb 0.605 0.680
a Values for patients vs. controls
b Values between different genotype carriers
p < 0.05 are in bold
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patients when compared to non-depressed control subjects
[16]. Additionally, we found increased levels of DNA lesions,
such as alkali labile sites and DNA strand breaks, in the
PBMCs isolated from depressed patients. The consequent
Table 5 Oxidative DNA damage recognized by Nth
Genotype Tail DNA (%), mean ± SEM pa
Controls Depression
Total
– 5.81 ± 0.21 12.57 ± 0.877 <0.001
NEIL1 c.*589G4C (rs4462560)
C/C 5.85 ± 0.28 12.56 ± 1.03 <0.001
C/G and G/G 5.75 ± 0.32 12.64 ± 1.62 <0.001
pb 0.642 0.823
hOGG1 c.977C>G (rs1052133)
C/C 5.96 ± 0.30 12.16 ± 1.05 <0.001
C/G and G/G 5.53 ± 0.25 13.65 ± 1.60 <0.001
pb 0.309 0.409
MUTYH c.972G>C (rs3219489)
C/C 5.84 ± 0.21 12.20 ± 0.91 <0.001
C/G and G/G 5.77 ± 0.51 13.15 ± 1.76 <0.001
pb 0.390 0.891
PARP1 c.2285T>C (rs1136410)
A/A 5.73 ± 0.31 12.25 ± 1.02 <0.001
A/G and G/G 5.93 ± 0.27 13.51 ± 1.75 <0.001
pb 0.335 0.297
XRCC1 c.1196A>G (rs25487)
C/C 5.71 ± 0.28 11.61 ± 0.99 <0.001
C/T 5.85 ± 0.35 12.73 ± 1.30 <0.001
T/T 6.01 ± 0.45 14.53 ± 3.49 0.017
pb 0.914 0.827
XRCC1 c.580C>T (rs1799782)
G/G 5.77 ± 0.24 12.78 ± 0,93 <0.001
G/A 6.08 ± 0.48 10.34 ± 1.50 0.004
pb 0.317 0.489
FEN1 c.-441G>A (rs174538)
G/G 5.83 ± 0.35 11.38 ± 0.80 <0.001
G/A 5.80 ± 0.25 14.40 ± 1.80 <0.001
pb 0.693 0.391
APEX1 c.-468T>G (rs1760944)
G/G 5.76 ± 0.39 13.00 ± 1.78 <0.001
G/T 5.98 ± 0.26 12.86 ± 1.16 <0.001
T/T 5.48 ± 0.59 10.12 ± 1.71 0.008
pb 0.523 0.539
APEX1 c.444T>G (rs1130409)
G/G 6.22 ± 0.55 14.98 ± 2.14 <0.001
G/T 5.62 ± 0.28 11.23 ± 1.29 <0.001
T/T 5.73 ± 0.22 12.15 ± 1.13 <0.001
pb 0.522 0.279
LIG1 c.-7C>T (rs20579)
G/G 5.89 ± 0.25 12.74 ± 1.09 <0.001
G/A and A/A 5.50 ± 0.34 12.17 ± 1.23 <0.001
pb 0.330 0.656
LIG3 c.*50C>T (rs1052536)
C/C 5.89 ± 0.39 10.07 ± 1.03 <0.001
C/T 5.98 ± 0.25 13.36 ± 1.54 <0.001
T/T 5.50 ± 0.52 12.87 ± 1.33 <0.001
pb 0.220 0.365
LIG3 c.*83A>C (rs4796030)
A/A 5.97 ± 0.42 11.32 ± 1.23 <0.001
A/C 5.94 ± 0.28 12.90 ± 1.70 <0.001
C/C 5.63 ± 0.41 12.59 ± 1.10 <0.001
pb 0.233 0.721
a Values for patients vs. controls
b Values between different genotype carriers
p < 0.05 are in bold
Table 4 Oxidative DNA damage recognized by hOGG1
Genotype Tail DNA (%), mean ± SEM pa
Controls Depression
Total
– 6.54 ± 0.22 14.88 ± 1.09 <0.001
NEIL1 c.*589G4C (rs4462560)
C/C 6.64 ± 0.30 14.63 ± 1.24 <0.001
C/G and G/G 6.36 ± 0.29 15.81 ± 2.42 <0.001
pb 0.695 0.541
hOGG1 c.977C>G (rs1052133)
C/C 6.56 ± 0.29 14.31 ± 1.27 <0.001
C/G and G/G 6.52 ± 0.32 16.34 ± 2.18 <0.001
pb 0.994 0,394
MUTYH c.972G>C (rs3219489)
C/C 6.43 ± 0.23 15.27 ± 1.29 <0.001
C/G and G/G 6.77 ± 0.50 14.28 ± 1.99 <0.001
pb 0.764 0.405
PARP1 c.2285T>C (rs1136410)
A/A 6.37 ± 0.29 14.54 ± 1.22 <0.001
A/G and G/G 6.81 ± 0.33 15.87 ± 2.47 <0.001
pb 0.273 0.568
XRCC1 c.1196A>G (rs25487)
C/C 6.49 ± 0.33 14.67 ± 1.70 <0.001
C/T 6.60 ± 0.34 14.70 ± 1.62 <0.001
T/T 6.43 ± 0.53 16.21 ± 2.98 0.004
pb 0.998 0.797
XRCC1 c.580C>T (rs1799782)
G/G 6.40 ± 0.24 15.27 ± 1.14 <0.001
G/A 7.34 ± 0.51 12.37 ± 3.47 0.064
pb 0.090 0.617
FEN1 c.-441G>A (rs174538)
G/G 6.38 ± 0.33 13.34 ± 1.14 <0.001
G/A 6.70 ± 0.30 17.24 ± 2.07 <0.001
pb 0.422 0.153
APEX1 c.-468T>G (rs1760944)
G/G 6.70 ± 0.39 14.68 ± 2.38 <0.001
G/T 6.37 ± 0.27 14.66 ± 1.46 <0.001
T/T 6.61 ± 0.70 16.51 ± 1.11 <0.001
pb 0.979 0.373
APEX1 c.444T>G (rs1130409)
G/G 7.27 ± 0.48 17.66 ± 2.85 <0.001
G/T 6.33 ± 0.28 12.10 ± 1.48 <0.001
T/T 6.06 ± 0.41 15.87 ± 1.20 <0.001
pb 0.126 0.076
LIG1 c.-7C>T (rs20579)
G/G 6.56 ± 0.26 15.04 ± 1.31 <0.001
G/A and A/A 6.44 ± 0.35 15.14 ± 1.90 0.001
pb 0.969 0.635
LIG3 c.*50C>T (rs1052536)
C/C 5.97 ± 0.28 13.48 ± 1.20 <0.001
C/T 6.62 ± 0.34 14.89 ± 1.89 <0.001
T/T 6.87 ± 0.47 15.61 ± 1.84 <0.001
pb 0.374 0.701
LIG3 c.*83A>C (rs4796030)
A/A 6.45 ± 0.39 14.76 ± 1.35 0.003
A/C 6.30 ± 0.31 14.35 ± 2.07 <0.001
C/C 6.84 ± 0.41 15.38 ± 1.46 <0.001
pb 0.789 0.423
a Values for patients vs. controls
b Values between different genotype carriers
p < 0.05 are in bold
Mol Neurobiol
question is whether the increased DNA damage is caused by
oxidative stress only or whether there are other contributing
factors. The results of Yi et al. obtained in patients with milder
forms of depression suggest the latter hypothesis because the
levels of urinary 8-oxoG in these patients were not significant-
ly different from those of the controls, suggesting that the
amount of oxidative DNA damage may be dependent on the
severity of the disease [15]. On the other hand, our previous
results showed that the PBMCs of depressed patients repaired
H2O2-inducedDNA damage slower than those of the controls,
suggesting an oxidative stress-independent mechanism [16].
One of the factors that may cause defective DNA damage
repair is the presence of specific polymorphic variants of
genes encoding proteins involved in this repair [18, 19].
Therefore, we genotyped 12 SNPs of BER genes in a larger
group consisting of more than 550 participants and found that
some of them can modulate rDD risk [17].
In the current work, we confirmed our previous results
concerning DNA damage and repair on a slightly larger group
than previously [16]. We found significantly greater amount of
alkali labile sites and strand breaks recognized by the alkaline
version of the comet assay in the PBMCs of cases when com-
pared to the controls (Table 3). Similarly, the level of oxidized
purines and pyrimidines, recognized by hOGG1 and Nth, re-
spectively, was higher in patients than in controls (Tables 4 and
5). These results are consistent with those of other authors
[9–14]. In the previous paper, we did not calculate DRE and,
therefore, cannot compare this parameter between the present
and our previous study [16]. However, the kinetics of DNA
damage repair was monitored and showed that the cells from
patients recovered more slowly than those of the controls, sug-
gesting that DNA damage was less efficiently repaired in pa-
tients. In the present study, the DRE values were significantly
lower in cases than in controls (Table 6), which is in agreement
with our previous results and suggests impairments in the mech-
anisms of genetic material maintenance.
Additionally, we genotyped 12 SNPs located within either
the coding or regulatory regions of genes involved in BER and
found that only the heterozygote of c.-468T>G–APEX1 sig-
nificantly increased the risk of depression (p = 0.037; Table 2).
Fig. 1 Efficiency of DNA damage repair in peripheral blood
mononuclear cells of patients with depression and the control group.
Horizontal lines denote the median, while whiskers show the
interquartile range
Table 6 Efficiency of DNA damage repair
Genotype DRE (%), mean ± SEM pa
Controls Depression
Total
– 43.39 ± 3.91 19.38 ± 4.31 <0.001
NEIL1 c.*589G4C (rs4462560)
C/C 39.16 ± 5.29 15.71 ± 4.91 <0.001
C/G and G/G 51.63 ± 4.82 33.26 ± 7.83 0.049
pb 0.333 0.098
hOGG1 c.977C>G (rs1052133)
C/C 41.82 ± 4.95 17.94 ± 4.49 <0.001
C/G and G/G 46.44 ± 6.46 23.09 ± 10.54 0.054
pb 0.476 0.599
MUTYH c.972G>C (rs3219489)
C/C 42.80 ± 4.97 15.12 ± 4.84 <0.001
C/G and G/G 44.62 ± 6.34 25.33 ± 7.95 0.064
pb 0.801 0.251
PARP1 c.2285T>C (rs1136410)
A/A 44.19 ± 5.31 17.34 ± 4.95 <0.001
A/G and G/G 42.14 ± 5.76 24.42 ± 8.93 0.066
pb 0.858 0.480
XRCC1 c.1196A>G (rs25487)
C/C 42.38 ± 5.31 15.87 ± 7.60 0.004
C/T 44.46 ± 5.76 15.75 ± 5.74 <0.001
T/T 41.55 ± 5.76 44.69 ± 7.41 0.840
pb 0.797 0.097
XRCC1 c.580C>T (rs1799782)
G/G 45.05 ± 4.24 19.76 ± 4.16 <0.001
G/A 34.18 ± 10.19 11.03 ± 32.20 0.370
pb 0.143 0.617
FEN1 c.-441G>A (rs174538)
G/G 38.13 ± 4.28 19.99 ± 4.97 0.008
G/A 48.48 ± 6.43 17.87 ± 8.00 0.001
pb 0.065 0.813
APEX1 c.-468T>G (rs1760944)
G/G 42.26 ± 7.47 9.83 ± 7.67 0.001
G/T 45.50 ± 4.25 21.35 ± 5.42 0.003
T/T 40.31 ± 11.55 25.48 ± 15.49 0.458
pb 0.935 0.480
APEX1 c.444T>G (rs1130409)
G/G 43.74 ± 6.50 11.90 ± 9.61 0.008
G/T 45.86 ± 4.42 16.00 ± 6.07 <0.001
T/T 38.41 ± 12.53 29.20 ± 7.06 0.152
pb 0.949 0.255
LIG1 c.-7C>T (rs20579)
G/G 40.37 ± 4.56 18.08 ± 5.15 <0.001
G/A and A/A 56.56 ± 5.37 22.68 ± 7.71 0.002
pb 0.158 0.675
LIG3 c.*50C>T (rs1052536)
C/C 42.44 ± 6.92 18.20 ± 9.66 0.052
C/T 49.02 ± 6.69 19.52 ± 6.24 <0.001
T/T 35.31 ± 6.37 19.17 ± 8.01 0.121
pb 0.100 0.994
LIG3 c.*83A>C (rs4796030)
A/A 51.64 ± 8.28 20.51 ± 11.63 0.047
A/C 46.10 ± 4.22 18.04 ± 6.82 <0.001
C/C 37.37 ± 7.87 19.81 ± 6.59 0.022
pb 0.541 0.976
a Values for patients vs. controls
b Values between different genotype carriers
p < 0.05 are in bold
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Table 7 Efficiency of DNA damage repair (DRE) of persons with
higher than the median DRE
Genotype DRE (%), mean ± SEM pa
Controls Depression
Total
– 62.56 ± 2.34 42.21 ± 3.13 <0.001
NEIL1 c.*589G4C (rs4462560)
C/C 60.37 ± 2.82 41.98 ± 3.77 0.004
C/G and G/G 66.93 ± 4.03 42.70 ± 6.06 0.003
pb 0.210 0.918
hOGG1 c.977C>G (rs1052133)
C/C 61.20 ± 2.87 38.29 ± 3.01 <0.001
C/G and G/G 64.90 ± 4.10 52.67 ± 6.94 0.125
pb 0.414 0.037
MUTYH c.972G>C (rs3219489)
C/C 61.40 ± 2.65 35.32 ± 2.60 <0.001
C/G and G/G 62.24 ± 4.90 52.04 ± 5.22 0.086
pb 0.619 0.005
PARP1 c.2285T>C (rs1136410)
A/A 65.35 ± 3.03 45.87 ± 4.04 <0.001
A/G and G/G 58.91 ± 3.54 36.93 ± 4.64 0.005
pb 0.155 0.165
XRCC1 c.1196A>G (rs25487)
C/C 61.88 ± 3.92 42.55 ± 6.93 0.009
C/T 63.17 ± 3.28 40.90 ± 4.20 <0.001
T/T 63.05 ± 6.92 44.69 ± 7.41 0.149
pb 0.836 0.899
XRCC1 c.580C>T (rs1799782)
G/G 63.02 ± 2.47 40.75 ± 2.90 <0.001
G/A 58.39 ± 8.59 72.96 ± 0.00 –
pb 0.213 –
FEN1 c.-441G>A (rs174538)
G/G 57.66 ± 2.63 39.61 ± 3.62 0.006
G/A 65.82 ± 3.32 46.77 ± 5.80 0.006
pb 0.244 0.282
APEX1 c.-468T>G (rs1760944)
G/G 66.20 ± 3.80 33.88 ± 2.44 0.005
G/T 58.42 ± 2.93 43.40 ± 3.71 0.003
T/T 67.60 ± 8.65 47.41 ± 14.04 0.252
pb 0.195 0.576
APEX1 c.444T>G (rs1130409)
G/G 60.28 ± 3.74 43.58 ± 6.43 0.032
G/T 64.08 ± 4.08 38.67 ± 4.40 0.002
T/T 62.65 ± 4.41 44.60 ± 5.84 0.029
pb 0.928 0.709
LIG1 c.-7C>T (rs20579)
G/G 61.57 ± 2.58 41.24 ± 3.37 <0.001
G/A and A/A 65.79 ± 5.61 46.61 ± 8.93 0.087
pb 0.556 0.521
LIG3 c.*50C>T (rs1052536)
C/C 60.12 ± 4.71 42.46 ± 6.37 0.051
C/T 64.53 ± 3.37 45.31 ± 5.15 0.036
T/T 59.81 ± 4.47 39.01 ± 5.20 0.016
pb 0.420 0.682
LIG3 c.*83A>C (rs4796030)
A/A 62.54 ± 4.91 38.36 ± 6.91 0.025
A/C 63.36 ± 3.82 45.70 ± 5.26 0.012
C/C 61.76 ± 3.99 40.72 ± 4.79 0.007
pb 0.946 0.701
a Values for patients vs. controls
b Values between different genotype carriers
p < 0.05 are in bold
Table 8 Efficiency of DNA damage repair (DRE) of persons with
lower than the median DRE
Genotype DRE (%), mean ± SEM pa
Controls Depression
Total
– 23.56 ± 5.57 −4.54 ± 3.66 <0.001
NEIL1 c.*589G4C (rs4462560)
C/C 16.84 ± 7.65 −5.04 ± 4.02 0.002
C/G and G/G 33.56 ± 5.69 0.22 ± 5.50 0.114
pb 0.156 0.684
hOGG1 c.977C>G (rs1052133)
C/C 23.42 ± 7.17 −3.76 ± 3.69 <0.001
C/G and G/G 23.88 ± 8.87 −6.49 ± 9.54 0.041
pb 0.981 0.754
MUTYH c.972G>C (rs3219489)
C/C 22.25 ± 7.71 −5.08 ± 4.79 0.002
C/G and G/G 26.06 ± 7.28 −3.65 ± 6.03 0.008
pb 0.731 0.855
PARP1 c.2285T>C (rs1136410)
A/A 25.26 ± 7.38 −2.18 ± 3.39 <0.001
A/G and G/G 20.33 ± 7.28 −26.96 ± 17.00 0.044
pb 0.477 0.043
XRCC1 c.1196A>G (rs25487)
C/C 8.26 ± 16.62 −4.14 ± 5.34 0.279
C/T and T/T 29.39 ± 8.44 −4.78 ± 5.08 <0.001
pb 0.213 0.934
XRCC1 c.580C>T (rs1799782)
G/G 23.95 ± 6.41 −2.92 ± 3.68 <0.001
G/A 22.47 ± 12.01 −19.93 ± 15.29 0.121
pb 0.809 0.179
FEN1 c.-441G>A (rs174538)
G/G 24.34 ± 4.76 −2.08 ± 4.41 <0.001
G/A 22.47 ± 12.01 −7.82 ± 6.33 0.017
pb 0.580 0.451
APEX1 c.-468T>G (rs1760944)
G/G 22.01 ± 10.62 −4.58 ± 8.15 0.025
G/T 24.82 ± 5.61 −4.52 ± 4.16 <0.001
T/T 18.49 ± 12.95 −7.40 ± 2.56 0.286
pb 0.905 0.974
APEX1 c.444T>G (rs1130409)
G/G 25.13 ± 9.67 −10.73 ± 8.12 0.029
G/T 30.26 ± 4.65 −3.07 ± 4.91 0.001
T/T 1.48 ± 5.70 −0.38 ± 23.64 0.310
pb 0.329 0.709
LIG1 c.-7C>T (rs20579)
G/G 20.87 ± 6.28 −9.05 ± 4.35 <0.001
G/A and A/A 40.41 ± 4.22 6.74 ± 4.38 <0.001
pb 0.242 0.048
LIG3 c.*50C>T (rs1052536)
C/C 24.76 ± 9.02 −6.05 ± 1.57 0.042
C/T 23.33 ± 13 −0.69 ± 4.78 0.003
T/T 23.06 ± 6.98 −10.59 ± 9.46 0.028
pb 0.717 0.522
LIG3 c.*83A>C (rs4796030)
A/A 29.84 ± 18.58 −6.26 ± 3.70 0.232
A/C 31.04 ± 4.33 −3.63 ± 4.16 <0.001
C/C 12.97 ± 11.61 −5.75 ± 6.78 0.082
pb 0.230 0.951
a Values for patients vs. controls
b Values between different genotype carriers
p < 0.05 are in bold
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This is consistent with our results (unpublished data) when the
genotyping was done on a larger group of 599 depressed par-
ticipants. Furthermore, other teams found that this polymor-
phismmodulates promoter strength and the risk of lung cancer
[30, 31]. We also observed that c.-468T>G–APEX1 modulat-
ed the risk of rDD in subjects with higher basal DNA damage
or lower oxidative DNA damage recognized by either Nth or
hOGG1 (Supplementary Tables 3, 6, and 8). Moreover, the
heterozygote of c.*589G>C–NEIL decreased the risk of de-
pression in cases with lower DRE as well as lower oxidative
DNA damage recognized by either Nth or hOGG1
(Supplementary Tables 2, 6, and 8), while the C/C homozy-
gote increased this risk in patients with lower oxidative DNA
damage recognized by Nth (Supplementary Table 6).
Interestingly, in a previous paper, we also found that the ho-
mozygotes of this polymorphism modulated the risk of de-
pression in a larger population of 555 participants [17]. This
could indicate that c.-468T>G–APEX1 and c.*589G>C–NEIL
are strongly associated with depression.
We also tested whether the presence of the studied polymor-
phisms affected endogenous DNA damage and DRE.We divid-
ed participants according to the genotypes that they were carry-
ing, and in all cases, endogenous basal DNAdamagewas higher
in patients than in controls. Moreover, in case of comparison
between genotype carriers within both groups, no difference in
DNA damage was noted (Table 3). The same results were ob-
tained for basal oxidative DNA damage recognized by either
Nth or hOGG1, with the exception of the heterozygote of
c.580C>T–XRCC1 where the difference between the cases
and controls was not statistically significant (Tables 4 and 5).
These results—showing independence between the level of
DNA damage and the SNP genotypes—may indicate that the
polymorphisms did not affect DNA damage or that this effect
was hidden by the damage caused by the disease itself. Either
way, this argues in favor of the hypothesis that the elevated
DNA damage found in depressed patients is mainly caused by
the oxidative stress associated with this disease. On the other
hand, our results obtained for DRE show that some polymorphic
variants may affect DNA damage repair. DRE did not vary
between the controls and the patients carrying the C/G and
G/G of c.977C>G–hOGG1, the C/G and G/G of c.972G>C–
MUTYH, the A/G and G/G of c.2285T>C–PARP1, the T/T of
c.580C>T–XRCC1, the G/A of c.1196A>G–XRCC1, the T/Tof
c.444T>G–APEX1, the T/T of c.-468T>G–APEX1, or the C/C
and T/T of c.*50C>T–LIG3 (Table 6). It must be noted that, in
all of these cases, the results did not differ between genotype
carriers in either patients or controls. However, when we con-
sidered only cases with higher than the median DRE values, we
found that this parameter was significantly greater in depressed
patients with the C/G and G/G genotypes of either c.977C>G–
hOGG1 or c.972G>C–MUTYH (Table 7). Additionally, in pa-
tients with lower DRE, this parameter was higher in carriers of
either the A/A of c.2285T>C–PARP1 or G/A and A/A of c.-
7C>T–LIG1 (Table 8). Thus, these results show that the DNA
lesions in depression may also originate from insufficient DNA
damage repair and are at least partly caused by the presence of




age at onset of depression and number of episodes. On the other
hand, similar studies had comparable number of participants [32,
33]. Secondly, we used PBMCs while examination of central
nervous system (CNS) cells would give more information on
the central aspects of the disease. Nevertheless, blood and CNS
cells are both exposed to oxidative and nitrosative stressors [34,
35],andthereforebloodcellsareagoodmodel toreflectwhatmay
happen in the CNS. The genetic constitution of PBMCs may
reveal inherited defects in the constitution of other systems, in-
cluding the CNS. Lastly, we genotyped only some SNPs while
there are more polymorphisms that could possibly contribute to
lowDRE in depressed patients.
Conclusion
This study shows that depression is accompanied by increased
oxidative stress-induced DNA damage combined with an im-
paired DNA damage repair efficiency. Furthermore, the latter
is in part related to specific SNPs of genes encoding proteins
involved in BER. This pathway may play a role in the patho-
genesis of depression and is likely a new drug target. Further
studies are needed to develop and examine new drugs
targeting oxidative stress, DNA damage, and DNA repair
mechanisms.
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